Phase I/II Study of S49076, a MET/AXL/FGFR Inhibitor, Combined with Gefitinib in NSCLC Patients Progressing on EGFR TKI
Abstract
Data di Pubblicazione:
2017
Citazione:
Phase I/II Study of S49076, a MET/AXL/FGFR Inhibitor, Combined with Gefitinib in NSCLC Patients Progressing on EGFR TKI / G. Chang, G.C.. - In: JOURNAL OF THORACIC ONCOLOGY. - ISSN 1556-0864. - 12:11 Supplement 2(2017 Nov), pp. MA 12.02.S1847-MA 12.02.S1848. (18. World Conference on Lung Cancer : October, 15th - 18th Yokohama (Japan) 2017) [10.1016/J.JTHO.2017.09.552].
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
EGFR tyrosine kinase inhibitor; MET / AXL inhibitor; Resistance;
Elenco autori:
G. Chang, G. Curigliano, W. Lim, S. Viteri, F. Ciardiello, T. Hida, C. Lin, H. Murakami, M. Nishio, L. Paz-Ares, F. Cantero, C. Gabarroca, E. Gandossi, N. Kamsu-Kom, S. Pennaforte, M.-. Secouard-Faure, K. Park
Link alla scheda completa: